Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted alpha-particle therapy

ABSTRACT: We used RNA sequencing to analyze the genomic signatures of prostate cancer that progressed after targeted alpha therapy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE147850 | GEO | 2020/04/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted ?-particle therapy.

Project description: Not available

| S-EPMC7334567 | biostudies-literature

Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted alpha-particle therapy

Project description:Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted alpha-particle therapy

| PRJNA622276 | ENA

Molecular pathways: targeted ?-particle radiation therapy.

Project description: Not available

| S-EPMC3563752 | biostudies-other

Spatial mapping of the biologic effectiveness of scanned particle beams: towards biologically optimized particle therapy.

Project description: Not available

| S-EPMC4650781 | biostudies-literature

Targeted genetic therapy for congenital melanocytic naevi

Project description:Transcriptome data on cells (immortalized and primary) treated with siRNA designed to preferentially target a mutant allele (NRASc.181C>A) over a WT allele

2024-01-01 | E-MTAB-13221 | biostudies-arrayexpress

IL13RA2 targeted alpha particle therapy against glioblastomas.

Project description: Not available

| S-EPMC5522122 | biostudies-other

A molecular signature for MET-targeted therapy

Project description:Constitutive MET signaling promotes invasiveness in primary and recurrent GBM; however, current MET-targeting strategies lack of effective biomarkers for selecting suitable patients for treatment. Here, we identified a predictive signature potentially valuable for indicating vulnerability to MET-targeted therapy in GBM. The use of both human and mouse gene expression microarrays showed that MET inhibitors regulate tumor (human) and host (mouse) cells within the tumor via distinct molecular processes, but overall they impede tumor growth by inhibiting cell cycle progression. Notably, GBM tumors with EGFRamp that showed resistance to erlotinib treatment also showed activation of the MET pathway, suggesting that a combination of EGFR and MET inhibitors may overcome or prevent such resistance in patients with EGFRamp GBM. GBM cell lines (DBM2, U251M2, U87M2, U118, and SF295) were treated for 7 days with either vehicle (n=14) or V-4084 (n=14) (i.e. SF295 + vehicle (n=2), SF295 + V-4084 (n=2), U118 + vehicle (n=3), U118 + V-4084 (n=3), U87M2 + vehicle (n=3), U87M2 + V-4084 (n=3), DBM2 + vehicle (n=3), DBM2 + V-4084 (n=3), U251M2 + vehicle (n=3), U251M2 + V-4084 (n=3)). GBM cell lines (DBM2, U251M2, U87M2, U118, and SF295) were subcutaneously inoculated into the flank region of nude mice to initiate tumor growth. Subsequently mice were treated for 7 days with either vehicle (n=14) or V-4084 (n=14) (i.e. SF295 + vehicle (n=2), SF295 + V-4084 (n=3), U118 + vehicle (n=3), U118 + V-4084 (n=3), U87M2 + vehicle (n=3), U87M2 + V-4084 (n=3), DBM2 + vehicle (n=3), DBM2 + V-4084 (n=3), U251M2 + vehicle (n=3), U251M2 + V-4084 (n=2)).

2016-01-05 | E-GEOD-64667 | biostudies-arrayexpress

Development of Targeted Alpha Particle Therapy for Solid Tumors.

Project description: Not available

| S-EPMC6930656 | biostudies-literature

Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma.

Project description: Not available

| S-EPMC7792624 | biostudies-literature

A molecular signature for MET-targeted therapy

2016-01-05 | GSE64667 | GEO